查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1831001

特發性肺纖維化治療市場

Idiopathic Pulmonary Fibrosis Treatment Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

特發性肺纖維化治療市場預計將從 2024 年的 65.6 億美元成長到 2031 年的 141 億美元，2025 年至 2031 年期間的複合年成長率預計為 12.0%。

分析師觀點：特發性肺纖維化是一種慢性疾病，會影響肺泡周圍的組織。由於不明原因，肺組織變得僵硬增厚，隨著時間的推移會形成永久性瘢痕，影響患者的呼吸。目前，特發性肺纖維化尚無根治方法。肺部復健、藥物治療和手術等治療方法旨在減緩肺部損傷並改善患者的生活品質。

特發性肺纖維化發生率的上升，加上吸菸人數的增加，推動了未來幾年對有效治療方案的需求。旨在開發特發性肺纖維化有效藥物的持續研究預計將在未來進一步促進市場成長。此外，已開發市場和新興市場的醫療保健支出都在成長，這可能會激勵製造商專注於開發新的創新產品。

市場概覽：纖維化是指結締組織的積聚，可作為正常癒合過程的一部分發生，也可作為病理狀態發生。特發性肺纖維化具體影響肺部和肺泡（肺泡）內的結締組織。這種疾病會導致健康人在日常非劇烈活動中出現呼吸困難。特發性肺纖維化治療市場的擴張與纖維化疾病盛行率的上升和吸菸率的上升有關。研發的快速進步預計將在不久的將來為特發性肺纖維化治療市場創造成長機會。

戰略洞察

市場驅動力：特發性肺纖維化發生率上升推動市場成長

根據美國肺臟協會2022年11月更新的資料，美國每年約有5萬例特發性肺纖維化新病例。此病症狀在50至70歲的人群中更為明顯。 2022年9月發表在《英國醫學雜誌》上的一篇文章指出，2021年專科護理單位中特發性肺纖維化的估計盛行率為每10萬人36.0例。由於老化、肥胖、高血壓和家族史等常見風險因素，全球特發性肺纖維化患者數量正在上升，這給社會經濟帶來了沉重的負擔。因此，特發性肺纖維化患者人數的增加支持了纖維化疾病治療市場的成長。

細分分析：特發性肺纖維化治療市場依藥物類型分為尼達尼布、吡非尼酮和其他藥物。尼達尼佈在2022年佔據了較大的市場佔有率，而其他藥物預計在2022年至2030年期間的複合年成長率將達到46.3%。吡非尼酮和尼達尼布是治療纖維化疾病最常用的處方藥。

區域分析：北美引領全球特發性肺纖維化治療市場，2022 年價值 23.6295 億美元，預計到 2030 年將達到 55.2728 億美元，2022-2030 年期間的預計複合年成長率為 11.2%。北美市場分為美國、加拿大和墨西哥。特發性肺纖維化發生率的上升和治療技術的進步有利於北美市場。主要參與者的產品發布和策略舉措也促進了市場成長。隨著旨在治療特發性肺纖維化的研發活動的增加，改進的藥物正在被引入，從而提高了更廣泛患者群體獲得治療的機會。此外，該地區廣泛的 FDA 批准鼓勵公司推出技術先進的產品。

歐洲特發性肺纖維化盛行率不斷上升，醫療支出也居高不下，在全球纖維化疾病治療市場中佔第二大佔有率。由於德國更容易獲得先進的醫療產品和服務，預計將引領歐洲特發性肺纖維化治療市場。

預計2022年至2030年，亞太地區將在全球特發性肺纖維化治療市場中呈現最快的複合年成長率。這項預期成長得益於創新技術的廣泛應用，這些技術能夠在顯著縮短的時間內提供準確的結果。該地區的醫療保健產業正在利用人工智慧、自動化和數位轉型方面的進步，提高醫務人員的效率和生產力。各行各業的持續轉型增強了亞太地區的企業和經濟實力，使其成為一個快速發展的樞紐，並以充滿活力和前瞻性的方式實現永續發展。

關鍵參與者分析：特發性肺纖維化治療市場的分析包括 Genentech, Inc. 和 Boehringer Ingelheim International GmbH 等關鍵參與者。

特發性肺纖維化治療市場報告範圍

最新動態：特發性肺纖維化治療市場的公司正在積極推行無機和有機策略，例如併購。一些最新動態包括：

2023年5月，勃林格殷格翰啟動了新型IL-11抑制劑抗體BI 765423的臨床開發。 1期臨床研究（NCT05658107）旨在評估其在健康志願者中的安全性、耐受性和藥物動力學。臨床前研究表明，該抗IL-11藥物在抑制並可能逆轉各種纖維化疾病的纖維化方面具有良好的效果。

2022年10月，勃林格殷格翰在FIBRONEER-IPF III期臨床試驗中招募了首位美國患者，該試驗旨在評估BI 1015550。 BI 1015550是一種實驗性磷酸二酯酶4B (PDE4B) 抑制劑，旨在治療特發性肺纖維化患者。該研究是全球FIBRONEER計畫的一部分，該計畫包含兩項III期臨床試驗：針對特發性肺纖維化患者的FIBRONEER-IPF和針對其他進行性纖維化間質性肺疾病(ILD)成人患者的FIBRONEER-ILD。

2022 年 9 月，Bellerophon Therapeutics, Inc. 宣布 FDA 接受了其減少正在進行的 INOpulse REBUILD 3 期註冊試驗規模的申請，該試驗用於治療纖維化間質性肺病 (LD)。

2022年5月，藥物安全解決方案領導者ArisGlobal收購了勃林格殷格翰旗下的BRASS數位創新技術。此次收購使ArisGlobal能夠透過將BRASS整合到LifeSphere Clarity中來增強其LifeSphere技術平台，從而提升整個行業的藥物警戒和患者安全。此外，ArisGlobal也擴大了其臨床診斷業務的全球影響力，鞏固了其市場地位。

2022年3月，百時美施貴寶宣布透過最終合併協議以每股76.00美元收購Turning Point Therapeutics, Inc.。此次收購顯著增強了百時美施貴寶在全球醫藥市場的影響力，使其能夠更積極主動地進行創新，同時擴大其救命療法和治療方案組合。

目錄

第1章：簡介

第2章：執行摘要

  • 關鍵見解
  • 市場吸引力分析

第3章：研究方法

第4章：特發性肺纖維化治療市場格局

  • 概述
  • PEST分析
  • 生態系分析
    • 價值鏈中的供應商列表

第5章：特發性肺纖維化治療市場－關鍵市場動態

  • 關鍵市場促進因素
  • 主要市場限制因素
  • 關鍵市場機會
  • 未來趨勢
  • 促進因素和限制因素的影響分析

第6章：特發性肺纖維化治療市場-全球市場分析

  • 特發性肺纖維化治療－全球市場概覽
  • 特發性肺纖維化治療－全球市場及2030年預測

第7章：特發性肺纖維化治療市場-收入分析-按藥物類型，2020-2030

  • 概述
  • 尼達尼布
  • 吡非尼酮
  • 其他

第 8 章：特發性肺纖維化治療市場 - 收入分析 - 按最終用戶，2020-2030 年

  • 概述
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第9章：特發性肺纖維化治療市場-收入分析，2020-2030-地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 歐洲其他地區
  • 亞太
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第10章：產業格局

  • 併購
  • 協議、合作、合資企業
  • 新產品發布
  • 擴張和其他策略發展

第 11 章：競爭格局

  • 關鍵參與者的熱圖分析
  • 公司定位與集中度

第 12 章：特發性肺纖維化治療市場 - 主要公司簡介

  • F. Hoffmann-La Roche Ltd
  • Boehringer Ingelheim
  • AstraZeneca
  • Bristol Myers Squibb
  • Shionogi and Co. Ltd.
  • Cipla Ltd
  • Others

第 13 章：附錄

簡介目錄
Product Code: TIPRE00005557

The market for idiopathic pulmonary fibrosis treatment is anticipated to grow from US$ 6.56 billion in 2024 to US$ 14.10 billion by 2031, with an estimated CAGR of 12.0% during the period from 2025 to 2031.

Analyst Perspective:Idiopathic pulmonary fibrosis is a chronic disease that impacts the tissue surrounding the alveoli in the lungs. It occurs when lung tissues become stiff and thick for unknown reasons, leading to permanent scarring over time, which complicates breathing for patients. At present, there is no definitive cure for idiopathic pulmonary fibrosis. Treatments such as pulmonary rehabilitation, medications, and surgical options aim to slow lung damage and improve the quality of life for patients.

The rising incidence of idiopathic pulmonary fibrosis, coupled with an increasing number of smokers, is driving the demand for effective treatment options in the upcoming years. Ongoing research aimed at developing effective drugs for idiopathic pulmonary fibrosis is expected to further enhance market growth in the future. Additionally, healthcare spending is on the rise in both developed and emerging markets, which is likely to motivate manufacturers to focus on creating new and innovative products.

Market Overview:Fibrosis refers to the accumulation of connective tissue that can occur as part of the normal healing process or as a pathological condition. Idiopathic pulmonary fibrosis specifically affects the connective tissue in the lungs and alveoli (the air sacs in the lungs). This condition can lead to shortness of breath during routine activities that are not strenuous for healthy individuals. The expansion of the idiopathic pulmonary fibrosis treatment market is linked to the increasing prevalence of fibrotic conditions and a rise in smoking rates. Rapid advancements in research and development are expected to create growth opportunities for the idiopathic pulmonary fibrosis treatment market in the near future.

Strategic Insights

Market Driver:Increasing Incidence of Idiopathic Pulmonary Fibrosis Fuels Market Growth

As per the American Lung Association's data updated in November 2022, around 50,000 new cases of idiopathic pulmonary fibrosis are diagnosed annually in the US. Symptoms of this condition are more pronounced in individuals aged 50 to 70. An article published in the British Medical Journal in September 2022 indicated that the estimated prevalence of idiopathic pulmonary fibrosis in specialized care units in 2021 was 36.0 per 100,000. The number of patients suffering from idiopathic pulmonary fibrosis is rising globally due to common risk factors such as aging, obesity, hypertension, and family history, making it a significant socioeconomic burden. Consequently, the increasing patient population with idiopathic pulmonary fibrosis supports the growth of the fibrotic disease treatment market.

Segmental Analysis:The idiopathic pulmonary fibrosis treatment market is categorized by drug type into nintedanib, pirfenidone, and others. The nintedanib segment held a larger market share in 2022, while the others segment is projected to achieve a higher CAGR of 46.3% from 2022 to 2030. Pirfenidone and nintedanib are the most commonly prescribed medications for treating fibrotic diseases.

Regional Analysis:North America leads the global idiopathic pulmonary fibrosis treatment market, valued at US$ 2,362.95 million in 2022 and expected to reach US$ 5,527.28 million by 2030, with a projected CAGR of 11.2% during 2022-2030. The North American market is divided into the US, Canada, and Mexico. The increasing incidence of idiopathic pulmonary fibrosis and advancements in treatment technologies are beneficial for the market in North America. Product launches and strategic initiatives by key players also contribute to market growth. With the rise in research and development activities aimed at treating idiopathic pulmonary fibrosis, improved medications are being introduced, enhancing access to treatments for a broader patient base. Furthermore, extensive FDA approvals in the region encourage companies to launch technologically advanced products.

Europe, with its rising prevalence of idiopathic pulmonary fibrosis and high healthcare spending, holds the second-largest share in the global fibrotic disease treatment market. Germany is expected to lead the European idiopathic pulmonary fibrosis treatment market due to better access to advanced healthcare products and services.

The Asia Pacific region is anticipated to exhibit the fastest CAGR in the global idiopathic pulmonary fibrosis treatment market from 2022 to 2030. This projected growth is attributed to the widespread adoption of innovative technologies that yield accurate results in a significantly shorter timeframe. Healthcare sectors across the region are leveraging advancements in artificial intelligence, automation, and digital transformation, enhancing efficiency and productivity among medical professionals. The ongoing transformation across various industries strengthens businesses and economies in the Asia Pacific, positioning them as a rapidly developing hub with a dynamic and forward-thinking approach to sustainable growth.

Key Player Analysis:The analysis of the idiopathic pulmonary fibrosis treatment market includes key players such as Genentech, Inc. and Boehringer Ingelheim International GmbH.

Idiopathic Pulmonary Fibrosis Treatment Market Report Scope

Recent Developments:Companies in the idiopathic pulmonary fibrosis treatment market are actively pursuing both inorganic and organic strategies, such as mergers and acquisitions. Some recent developments include:

In May 2023, Boehringer Ingelheim began clinical development of BI 765423, a novel IL-11 inhibitor antibody. The Phase 1 study (NCT05658107) aims to assess its safety, tolerability, and pharmacokinetics in healthy volunteers. Preclinical studies have shown promising results for this anti-IL-11 drug in inhibiting and potentially reversing fibrosis in various fibrotic conditions.

In October 2022, Boehringer Ingelheim enrolled the first US patient in the FIBRONEER-IPF Phase III study evaluating BI 1015550, an experimental phosphodiesterase 4B (PDE4B) inhibitor designed for treating individuals with idiopathic pulmonary fibrosis. This study is part of the global FIBRONEER program, which includes two Phase III studies: FIBRONEER-IPF for idiopathic pulmonary fibrosis patients and FIBRONEER-ILD for adults with other progressive fibrosing interstitial lung diseases (ILDs).

In September 2022, Bellerophon Therapeutics, Inc. announced that the FDA accepted its application for reducing the trial size for the ongoing REBUILD Phase 3 registration trial of INOpulse, indicated for the treatment of fibrotic interstitial lung disease (LD).

In May 2022, ArisGlobal, a leader in drug safety solutions, acquired Boehringer Ingelheim's BRASS digital innovation. This acquisition allowed ArisGlobal to enhance its LifeSphere technology platform by integrating BRASS into LifeSphere Clarity, advancing pharmacovigilance and patient safety across the industry. Additionally, ArisGlobal has expanded its clinical diagnostics business presence globally, strengthening its position.

In March 2022, Bristol Myers Squibb announced the acquisition of Turning Point Therapeutics, Inc. for US$ 76.00 per share through a definitive merger agreement. This acquisition significantly bolstered Bristol Myers Squibb's global presence in the pharmaceutical market, enabling it to be more proactive in delivering innovations while expanding its portfolio of life-saving therapies and treatments.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Idiopathic Pulmonary Fibrosis Treatment Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Idiopathic Pulmonary Fibrosis Treatment Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Idiopathic Pulmonary Fibrosis Treatment Market - Global Market Analysis

  • 6.1 Idiopathic Pulmonary Fibrosis Treatment - Global Market Overview
  • 6.2 Idiopathic Pulmonary Fibrosis Treatment - Global Market and Forecast to 2030

7. Idiopathic Pulmonary Fibrosis Treatment Market - Revenue Analysis (USD Million) - By Drug Type, 2020-2030

  • 7.1 Overview
  • 7.2 Nintedanib
  • 7.3 Pirfenidone
  • 7.4 Others

8. Idiopathic Pulmonary Fibrosis Treatment Market - Revenue Analysis (USD Million) - By End User, 2020-2030

  • 8.1 Overview
  • 8.2 Hospitals Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies

9. Idiopathic Pulmonary Fibrosis Treatment Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 9.1 North America
    • 9.1.1 North America Idiopathic Pulmonary Fibrosis Treatment Market Overview
    • 9.1.2 North America Idiopathic Pulmonary Fibrosis Treatment Market Revenue and Forecasts to 2030
    • 9.1.3 North America Idiopathic Pulmonary Fibrosis Treatment Market Revenue and Forecasts and Analysis - By Drug Type
    • 9.1.4 North America Idiopathic Pulmonary Fibrosis Treatment Market Revenue and Forecasts and Analysis - By End User
    • 9.1.5 North America Idiopathic Pulmonary Fibrosis Treatment Market Revenue and Forecasts and Analysis - By Countries
      • 9.1.5.1 United States Idiopathic Pulmonary Fibrosis Treatment Market
        • 9.1.5.1.1 United States Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Type
        • 9.1.5.1.2 United States Idiopathic Pulmonary Fibrosis Treatment Market, by End User
      • 9.1.5.2 Canada Idiopathic Pulmonary Fibrosis Treatment Market
        • 9.1.5.2.1 Canada Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Type
        • 9.1.5.2.2 Canada Idiopathic Pulmonary Fibrosis Treatment Market, by End User
      • 9.1.5.3 Mexico Idiopathic Pulmonary Fibrosis Treatment Market
        • 9.1.5.3.1 Mexico Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Type
        • 9.1.5.3.2 Mexico Idiopathic Pulmonary Fibrosis Treatment Market, by End User
  • 9.2 Europe
    • 9.2.1 Germany
    • 9.2.2 France
    • 9.2.3 Italy
    • 9.2.4 Spain
    • 9.2.5 United Kingdom
    • 9.2.6 Rest of Europe
  • 9.3 Asia-Pacific
    • 9.3.1 Australia
    • 9.3.2 China
    • 9.3.3 India
    • 9.3.4 Japan
    • 9.3.5 South Korea
    • 9.3.6 Rest of Asia-Pacific
  • 9.4 Middle East and Africa
    • 9.4.1 South Africa
    • 9.4.2 Saudi Arabia
    • 9.4.3 U.A.E
    • 9.4.4 Rest of Middle East and Africa
  • 9.5 South and Central America
    • 9.5.1 Brazil
    • 9.5.2 Argentina
    • 9.5.3 Rest of South and Central America

10. Industry Landscape

  • 10.1 Mergers and Acquisitions
  • 10.2 Agreements, Collaborations, Joint Ventures
  • 10.3 New Product Launches
  • 10.4 Expansions and Other Strategic Developments

11. Competitive Landscape

  • 11.1 Heat Map Analysis by Key Players
  • 11.2 Company Positioning and Concentration

12. Idiopathic Pulmonary Fibrosis Treatment Market - Key Company Profiles

  • 12.1 F. Hoffmann-La Roche Ltd
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Boehringer Ingelheim
  • 12.3 AstraZeneca
  • 12.4 Bristol Myers Squibb
  • 12.5 Shionogi and Co. Ltd.
  • 12.6 Cipla Ltd
  • 12.7 Others

13. Appendix

  • 13.1 Glossary
  • 13.2 About The Insight Partners
  • 13.3 Market Intelligence Cloud